Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer
Copyright © 2023 Elsevier Ltd. All rights reserved..
Cancer involves cells' abnormal growth and ability to invade or metastasize to different body parts. Cancerous cells can divide uncontrollably and spread to other areas through the lymphatic or circulatory systems. Tumors form when malignant cells clump together in an uncontrolled manner. In this context, the cytokine interferon-gamma (IFN-γ) is crucial in regulating immunological responses, particularly malignancy. While IFN-γ is well-known for its potent anti-tumor effects by activating type 1 immunity, recent research has revealed its ability to suppress type 2 immunity, associated with allergy and inflammatory responses. This review aims to elucidate the intricate function of IFN-γ in inhibiting type 2 immune responses to cancer. We explore how IFN-γ influences the development and function of immune cells involved in type 2 immunity, such as mast cells, eosinophils, and T-helper 2 (Th2) cells. Additionally, we investigate the impact of IFN-mediated reduction of type 2 immunity on tumor development, metastasis, and the response to immunotherapeutic interventions. To develop successful cancer immunotherapies, it is crucial to comprehend the complex interplay between type 2 and type 1 immune response and the regulatory role of IFN-γ. This understanding holds tremendous promise for the development of innovative treatment approaches that harness the abilities of both immune response types to combat cancer. However, unraveling the intricate interplay between IFN-γ and type 2 immunity in the tumor microenvironment will be essential for achieving this goal.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:171 |
|---|---|
| Enthalten in: |
Cytokine - 171(2023) vom: 05. Nov., Seite 156376 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bhat, Asif Ahmad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 08.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.cyto.2023.156376 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362447136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362447136 | ||
| 003 | DE-627 | ||
| 005 | 20231226091249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cyto.2023.156376 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362447136 | ||
| 035 | |a (NLM)37748333 | ||
| 035 | |a (PII)S1043-4666(23)00254-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bhat, Asif Ahmad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Cancer involves cells' abnormal growth and ability to invade or metastasize to different body parts. Cancerous cells can divide uncontrollably and spread to other areas through the lymphatic or circulatory systems. Tumors form when malignant cells clump together in an uncontrolled manner. In this context, the cytokine interferon-gamma (IFN-γ) is crucial in regulating immunological responses, particularly malignancy. While IFN-γ is well-known for its potent anti-tumor effects by activating type 1 immunity, recent research has revealed its ability to suppress type 2 immunity, associated with allergy and inflammatory responses. This review aims to elucidate the intricate function of IFN-γ in inhibiting type 2 immune responses to cancer. We explore how IFN-γ influences the development and function of immune cells involved in type 2 immunity, such as mast cells, eosinophils, and T-helper 2 (Th2) cells. Additionally, we investigate the impact of IFN-mediated reduction of type 2 immunity on tumor development, metastasis, and the response to immunotherapeutic interventions. To develop successful cancer immunotherapies, it is crucial to comprehend the complex interplay between type 2 and type 1 immune response and the regulatory role of IFN-γ. This understanding holds tremendous promise for the development of innovative treatment approaches that harness the abilities of both immune response types to combat cancer. However, unraveling the intricate interplay between IFN-γ and type 2 immunity in the tumor microenvironment will be essential for achieving this goal | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a IFN-γ signaling | |
| 650 | 4 | |a T-helper 2 | |
| 650 | 4 | |a Type 2 immunity | |
| 700 | 1 | |a Goyal, Ahsas |e verfasserin |4 aut | |
| 700 | 1 | |a Thapa, Riya |e verfasserin |4 aut | |
| 700 | 1 | |a Almalki, Waleed Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Kazmi, Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Alzarea, Sami I |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Mahaveer |e verfasserin |4 aut | |
| 700 | 1 | |a Rohilla, Suman |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Tarun Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kukreti, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Meenakshi, Dhanalekshmi Unnikrishnan |e verfasserin |4 aut | |
| 700 | 1 | |a Fuloria, Neeraj Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Sekar, Mahendran |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytokine |d 1994 |g 171(2023) vom: 05. Nov., Seite 156376 |w (DE-627)NLM012645575 |x 1096-0023 |7 nnns |
| 773 | 1 | 8 | |g volume:171 |g year:2023 |g day:05 |g month:11 |g pages:156376 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cyto.2023.156376 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 171 |j 2023 |b 05 |c 11 |h 156376 | ||